United Therapeutics Corporation (UTHR) has entered into a comprehensive settlement agreement with Liquidia Technologies, Inc. to resolve all pending patent infringement and trade secrets litigation between the two companies. As part of the agreement, Liquidia will make total payments of $330.4 million to United Therapeutics and will cease promoting its drug Yutrepia® for a key indication.
Key Details
- Financial Terms: Liquidia will pay United Therapeutics an aggregate of $330.4 million. This includes $185 million for past damages (payable within 30 business days) and $145.4 million for future damages (payable in two installments by April 30, 2027).
- Yutrepia® Indication Change: Liquidia has agreed to immediately file with the FDA to remove the pulmonary hypertension associated with interstitial lung disease (PH-ILD) indication from Yutrepia's® labeling and will cease all marketing and sales for this indication upon FDA approval.
- Litigation Dismissal: The settlement resolves multiple lawsuits, including patent infringement cases related to Yutrepia® and Tyvaso DPI®, as well as trade secrets litigation. United Therapeutics will also pay $10.0 million to settle related antitrust litigation initiated by a Liquidia subsidiary.